Tag Archives: Roche’s

In a first, MorphoSys, Incyte win Monjuvi FDA nod in lymphoma to challenge Roche’s Polivy

The FDA hasn’t specifically approved a therapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after an initial line of therapy—until now. MorphoSys and Incyte’s Monjuvi—also known as tafasitamab—in combination with Celgene’s Revlimid now represents the first FDA-approved second-line regimen for DLBCL, the two companies said Friday. Because of Monjuvi’s importance… Read More »

Roche’s Tecentriq-Avastin lung cancer combo gets a lift from England’s cost watchdogs

Roche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lung cancer. The National Institute of Health and Care Excellence (NICE) decided to back the immuno-oncology drug, in combination with Roche’s Avastin and chemo,… Read More »